Active — Not RecruitingPhase 3

FINEPKT - Finerenone in Proteinuria Patients After Kidney Transplan

China54 participantsStarted 2025-01-30

Plain-language summary

The goal of this clinical trial is to learn if Finerenone works to treat proteinuria patients after kidney transplantation. It will also learn about the safety of Finerenone. The main questions it aims to answer are: Does Finerenone lower the number of UACR values in kidney transplant recipients?? What medical problems do participants have when taking Finerenone? Researchers will compare Finerenone to Dapagliflozin to see if Finerenone works to treat proteinuria patients after kidney transplantation.

Who can participate

Age range19 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Persistent high proteinuria (UACR of 30-300 mg/g, more than 2 of 3 early morning urination samples) and estimated glomerular filtration rate (eGFR) of 25-60ml/min/1.73m2 (CKD EPI) and the presence of diabetic retinopathy.
✓. Persistent extremely high albuminuria (UACR≥300mg/g, more than 2 of 3 early morning urination samples) and eGFR≤25 mL /min/1.73m2 (CKD EPI) 3. Previous treatments with angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor block (ARB) are as follows: A. At least 4 weeks prior to the run-in visit, subjects should receive ACEI or ARB or a combination of both

What they're measuring

Urine Albumin-to-Creatinine Ratio

Timeframe: From enrollment to the end of treatment at 6 months"

creatinine

Timeframe: From enrollment to the end of treatment at 6 months"

Trial details

NCT IDNCT07356388

Sponsorkewen Chen,MD

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-10-01

View on ClinicalTrials.gov More Kidney Transplantation Recipients trials